Literature DB >> 17762335

The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours.

Patti A Groome1, Vanessa Bolejack, John J Crowley, Catherine Kennedy, Mark Krasnik, Leslie H Sobin, Peter Goldstraw.   

Abstract

INTRODUCTION: In 1996, the International Association for the Study of Lung Cancer (IASLC) launched a worldwide TNM staging project to inform the next edition (seventh) of the TNM lung cancer staging system. In this article, we describe the methods and validation approaches used and discuss the internal and external validity of the recommended changes.
METHODS: The International Staging Committee agreed on a number of general principles that guided the decision-making process. Internal validity was addressed by visually assessing the consistency of Kaplan-Meier curves across database types, geographic regions and addressing external validity, by assessing the similarity of curves generated using the population-based Surveillance Epidemiology and End Results cancer registry data to those generated using the project database. Cox proportional hazards regression was used to calculate hazard ratios between the proposed stage groupings with adjustment for cell type, sex, age, and region.
RESULTS: Calls for data by the International Staging Committee resulted in the creation of an international database containing information on more than 100,000 cases. The present work is based on analyses of the 67,725 cases of non-small cell lung cancer. Validation checks were robust, demonstrating that the suggested staging changes are stable within the data sources used and externally. For example, suggested changes based on tumor size were well supported, with statistically significant hazard ratios ranging from 1.14 to 1.51 between adjacent pairs in the Surveillance Epidemiology and End Results data.
CONCLUSIONS: Lung cancer stage definitions have never been subjected to such an intense validation process. We do accept, however, that this work is limited in ways that can only be addressed by a prospective database, which we intend to develop. In the meantime, we think that this new system will greatly improve the usefulness of TNM lung staging across all of its purposes.

Entities:  

Mesh:

Year:  2007        PMID: 17762335     DOI: 10.1097/JTO.0b013e31812d05d5

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  181 in total

1.  Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.

Authors:  Charles B Simone; Jay F Dorsey
Journal:  Ann Transl Med       Date:  2015-08

2.  IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance.

Authors:  Xueyan Zhang; Jiayuan Sun; Huimin Wang; Yuqing Lou; Yanwei Zhang; Huifang Sha; Jiuxian Feng; Baohui Han
Journal:  Tumour Biol       Date:  2013-08-29

3.  The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.

Authors:  Pamela Samson; Aalok Patel; Cliff G Robinson; Daniel Morgensztern; Su-Hsin Chang; Graham A Colditz; Saiama Waqar; Traves D Crabtree; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-08-25       Impact factor: 4.330

4.  The 7th lung cancer TNM classification and staging system: Review of the changes and implications.

Authors:  Saeed Mirsadraee; Dilip Oswal; Yalda Alizadeh; Andrea Caulo; Edwin van Beek
Journal:  World J Radiol       Date:  2012-04-28

5.  Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Authors:  Joshua H Finkle; Stephanie Y Jo; Mark K Ferguson; Hai-Yan Liu; Chenpeng Zhang; Xuee Zhu; Cindy Yuan; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-07       Impact factor: 9.236

6.  National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers.

Authors:  Edward F Patz; Neil E Caporaso; Steven M Dubinett; Pierre P Massion; Fred R Hirsch; John D Minna; Constantine Gatsonis; Fenghai Duan; Amanda Adams; Charles Apgar; Rosa M Medina; Denise R Aberle
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

7.  Outcomes: wedge resection versus lobectomy for non-small cell lung cancer at the Cancer Centre of Southeastern Ontario 1998-2009.

Authors:  Anna L McGuire; Wilma M Hopman; Dimitri Petsikas; Ken Reid
Journal:  Can J Surg       Date:  2013-12       Impact factor: 2.089

8.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 9.  Photodynamic therapy for lung cancer and malignant pleural mesothelioma.

Authors:  Charles B Simone; Keith A Cengel
Journal:  Semin Oncol       Date:  2014-10-07       Impact factor: 4.929

10.  Impact of main bronchial lymph node involvement in pathological T1-2N1M0 non-small-cell lung cancer: multi-institutional survey by the Japan National Hospital Study Group for Lung Cancer.

Authors:  Hajime Maeda; Shimao Fukai; Akihide Matsumura; Osamu Kawashima; Takehiro Watanabe; Takeshi Yamanda; Kan Okabayashi; Yuka Fujita; Atsuhisa Tamura; Masaaki Kawahara
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.